nach oben

Erschienen in:

01.01.2012 | Research

The Behavior of Matrix Metalloproteinase-9 in Lymphocytic Colitis, Collagenous Colitis and Ulcerative Colitis

verfasst von: Gábor Lakatos, Ferenc Sipos, Pál Miheller, István Hritz, Mária Zsófia Varga, Márk Juhász, Béla Molnár, Zsolt Tulassay, László Herszényi

Erschienen in: Pathology & Oncology Research | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

Matrix metalloproteinases play an important role in extracellular matrix remodelling. It has been proposed that matrix metalloproteinase-9 (MMP-9) is involved in epithelial damage in ulcerative colitis (UC). However, to our knowledge, no data are available in terms of MMP-9 expression in microscopic colitis. Determination of mucosal protein expression levels of MMP-9 in lymphocytic colitis (LC), collagenous colitis (CC) and UC. MMP-9 immunohistochemical expressions were analyzed in paraffin-embedded tissue samples by immunohistochemistry including patients with LC, CC, UC, active diverticulitis, inactive diverticular disease and healthy control subjects. UC was also subgrouped according to the severity of inflammation. Immunostaining was determined semiquantitatively. Independent colonic biopsies from healthy and severe UC cases were used for gene expression analyses. For further comparison MMP-9 serum antigen levels were also determined in patients with UC and control patients without macroscopic or microscopic changes during colonoscopy. MMP-9 mucosal expression was significantly higher in UC (26.7 ± 19.5%) compared to LC (6.6 ± 9.3%), CC (6.4 ± 7.6%), active diverticulitis (5.33 ± 2.4%), inactive diverticular disease (5.0 ± 2.2%) and controls (6.3 ± 2.6%) (P < 0.001). The immunohistochemical expression of MMP-9 in LC and CC was similar as compared to controls. MMP-9 expression was significantly higher in each inflammatory group of UC compared to controls (mild: 11.0 ± 2.8%, moderate: 23.9 ± 3.7%, severe UC: 52.6 ± 3.9% and 6.3 ± 2.6%, respectively, P < 0.005). The gene expression microarray data and RT-PCR results demonstrated a significantly higher expression of MMP-9 in severely active UC compared to healthy controls (P < 0.001). Significantly higher MMP-9 serum antigen concentrations were observed in UC patients compared with the control group (P < 0.05). MMP-9 seems to play no role in the inflammatory process of LC and CC. In contrast, the mucosal up-regulation of MMP-9 correlated with the severity of inflammation in UC. The increased MMP-9 expression could contribute to the severity of mucosal damage in active UC.

Kirsner JB (2001) Historical origins of current IBD concepts. World J Gastroenterol 7:175–184PubMed

Kucharzik T, Maaser C, Lugering A, Kagnoff M, Mayer L, Targan S, Domschke W (2006) Recent understanding of IBD pathogenesis: implications for future therapies. Inflamm Bowel Dis 12:1068–1083PubMedCrossRef

Liotta LA, Stetler-Stevenson WG (1991) Tumor invasion and metastasis: an imbalance of positive and negative regulation. Cancer Res 51:5054–5059

Plebani M, Herszényi L, Cardin R, Roveroni G, Carraro P, De Paoli M, Rugge M, Nitti D, Naccarato R, Farinati F (1995) Cysteine and serine proteases in gastric cancer. Cancer 76:367–375PubMedCrossRef

Herszényi L, Plebani M, Carraro P, De Paoli M, Roveroni R, Cardin R, Tulassay Zs, Naccarato R, Farinati F (1999) The role of cysteine and serine proteases in colorectal cancer. Cancer 86:1135–1142PubMedCrossRef

Herszényi L, Farinati F, Cardin R, István G, Molnár DL, Hritz I, De Paoli M, Plebani M, Tulassay Z (2008) Tumor marker utility and prognostic relevance of cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 in colorectal cancer. BMC Cancer 8:194. doi:10.1186/1471-2407-8-194 PubMedCrossRef

Herszényi L, Plebani M, Carraro P, De Paoli M, Di Mario F, Kusstatscher S, Rugge M, Cardin R, Naccarato R, Farinati F (1997) Impaired fibrinolysis and increased protease levels in gastric and duodenal mucosa of patients with active duodenal ulcer. Am J Gastroenterol 92:843–847PubMed

Herszényi L, István G, Cardin R, De Paoli M, Plebani M, Tulassay Z, Farinati F (2008) Serum cathepsin B and plasma urokinase-type plasminogen activator levels in gastrointestinal tract cancers. Eur J Cancer Prev 17:438–445PubMedCrossRef

Baugh MD, Perry MJ, Hollander AP, Davies DR, Cross SS, Lobo AJ, Taylor CJ, Evans GS (1999) Matrix metalloproteinase levels are elevated in inflammatory bowel disease. Gastroenterology 117:814–822PubMedCrossRef

10.

von Lampe B, Barthel B, Coupland SE, Riecken EO, Rosewicz S (2000) Differential expression of matrix metalloproteinases and their tissue inhibitors in colon mucosa of patients with inflammatory bowel disease. Gut 47:63–73CrossRef

11.

Monteleone G, Caruso R, Fina D, Peluso I, Gioia V, Stolfi C, Fantini MC, Caprioli F, Tersigni R, Alessandroni L, MacDonald TT, Pallone F (2006) Control of matrix metalloproteinase production in human intestinal fibroblasts by interleukin 21. Gut 55:1774–1780PubMedCrossRef

12.

Ravi A, Garg P, Sitaraman SV (2007) Matrix metalloproteinases in inflammatory bowel disease: Boon or a baine? Inflamm Bowel Dis 13:97–107PubMedCrossRef

13.

Herszényi L, Hritz I, Pregun I, Sipos F, Juhász M, Molnár B, Tulassay Z (2007) Alterations of glutathione S-transferase and matrix metalloproteinase-9 expressions are early events in the esophageal carcinogenesis. World J Gastroenterol 13:676–682PubMed

14.

Herszényi L, Sipos F, Galamb O, Solymosi N, Hritz I, Miheller P, Berczi L, Molnár B, Tulassay Z (2008) Matrix metalloproteinase-9 expression in the normal mucosa-adenoma-dysplasia-adenocarcinoma sequence of the colon. Pathol Oncol Res 14(1):31–37PubMedCrossRef

15.

Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM (2000) Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 18:1135–1149PubMed

16.

Kirkegaard T, Hansen A, Bruun E, Brynskov J (2004) Expression and localisation of matrix metalloproteinases and their natural inhibitors in fistulae of patients with Crohn’s disease. Gut 53:701–709PubMedCrossRef

17.

Bailey CJ, Hembry RM, Alexander A, Irving MH, Grant ME, Shuttleworth CA (1994) Distribution of the matrix metalloproteinases stromelysin, gelatinases A and B, and collagenase in Crohn’s disease and normal intestine. J Clin Pathol 47:113–116PubMedCrossRef

18.

Stallmach A, Chan CC, Ecker KW, Feifel G, Herbst H, Schuppan D, Zeitz M (2000) Comparable expression of matrix metalloproteinases 1 and 2 in pouchitis and ulcerative colitis. Gut 47:415–422PubMedCrossRef

19.

Von Lampe B, Barthel B, Coupland SE, Riecken EO, Rosewicz S (2000) Differential expression of matrix metalloproteinases and their tissue inhibitors in colon mucosa of patients with inflammatory bowel disease. Gut 47:63–73CrossRef

20.

Nielsen OH, Vainer B, de Muckadell OB (2004) Microscopic colitis: a missed diagnosis? Lancet 364:2055–2057PubMedCrossRef

21.

Aqel B, Bishop M, Krishna M, Cangemi J (2003) Collagenous colitis evolving into ulcerative colitis: a case report and review of the literature. Dig Dis Sci 48:2323–2327PubMedCrossRef

22.

Sipos F, Molnár B, Zágoni T, Berczi L, Tulassay Z (2005) Growth in epithelial cell proliferation and apoptosis correlates specifically to the inflammation activity of inflammatory bowel disease: ulcerative colitis shows specific p53- and EGFR expression alterations. Dis Colon Rectum 48:775–786PubMedCrossRef

23.

Galamb O, Sipos F, Dinya E, Spisak S, Tulassay Z, Molnar B (2006) mRNA expression, functional profiling and multivariate classification of colon biopsy specimen by cDNA overall glass microarray. World J Gastroenterol 12:6998–7006PubMed

24.

Medina C, Radomski MW (2006) Role of matrix metalloproteinases in intestinal inflammation. J Pharmacol Exp Ther 318(3):933–938PubMedCrossRef

25.

Pender SL, Tickle SP, Docherty AJ, Howie D, Wathen NC, MacDonald TT (1997) A major role for matrix metalloproteinases in T cell injury in the gut. J Immunol 158(4):1582–1590PubMed

26.

Gordon JN, Pickard KM, Di Sabatino A, Prothero JD, Pender SL, Goggin PM, MacDonald TT (2008) Matrix metalloproteinase-3 production by gut IgG plasma cells in chronic inflammatory bowel disease. Inflamm Bowel Dis 14(2):195–203PubMedCrossRef

27.

Garg P, Vijay-Kumar M, Wang L, Gewirtz AT, Merlin D, Sitaraman SV (2009) Matrix metalloproteinase-9-mediated tissue injury overrides the protective effect of matrix metalloproteinase-2 during colitis. Am J Physiol Gastrointest Liver Physiol 296:175–184CrossRef

28.

Nyhlin N, Bohr J, Eriksson S, Tysk C (2006) Systematic review: microscopic colitis. Aliment Pharmacol Ther 23(11):1525–1534PubMedCrossRef

29.

Gao Q, Meijer MJ, Kubben FJ, Sier CF, Kruidenier L, van Duijn W, van den Berg M, van Hogezand RA, Lamers CB, Verspaget HW (2005) Expression of matrix metalloproteinases-2 and -9 in intestinal tissue of patients with inflammatory bowel diseases. Dig Liver Dis 37:584–592PubMedCrossRef

30.

31.

Manfredi MA, Zurakowski D, Rufo PA, Walker TR, Fox VL, Moses MA (2008) Increased incidence of urinary matrix metalloproteinases as predictors of disease in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis 14:1091–1096PubMedCrossRef

32.

Castaneda FE, Walia B, Vijay-Kumar M, Patel NR, Roser S, Kolachala VL, Rojas M, Wang L, Oprea G, Garg P, Gewirtz AT, Roman J, Merlin D, Sitaraman SV (2005) Targeted deletion of metalloproteinase 9 attenuates experimental colitis in mice: central role of epithelial-derived MMP. Gastroenterology 129:1991–2008PubMedCrossRef

33.

Martinesi M, Treves C, Bonanomi AG, Milla M, Bagnoli S, Zuegel U, Steinmeyer A, Stio M (2010) Down-regulation of adhesion molecules and matrix metalloproteinases by ZK 156979 in inflammatory bowel diseases. Clin Immunol 136:51–60PubMedCrossRef

34.

Meijer MJ, Mieremet-Ooms MA, van Duijn W, van der Zon AM, Hanemaaijer R, Verheijen JH, van Hogezand RA, Lamers CB, Verspaget HW (2007) Effect of the tumor necrosis factor-alpha antibody infliximab on the ex vivo mucosal matrix metalloproteinase-proteolytic phenotype in inflammatory bowel disease. Inflamm Bowel Dis 13:200–210PubMedCrossRef

35.

Di Sabatino A, Pender SL, Jackson CL, Prothero JD, Gordon JN, Picariello L, Rovedatti L, Docena G, Monteleone G, Ramtpon DS, Tonelli F, Corazza GR, MacDonald TT (2007) Functional modulation of Crohn’s disease myofibroblasts by anti-tumor necrosis factor antibodies. Gastroenterology 133:137–149PubMedCrossRef

36.

Wang YD, Yan PY (2006) Expression of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in ulcerative colitis. World J Gastroenterol 12:6050–6053PubMed

37.

Kobayashi K, Arimura Y, Goto A, Okahara S, Endo T, Shinomura Y, Imai K (2006) Therapeutic implications of the specific inhibition of causative matrix metalloproteinases in experimental colitis induced by dextran sulphat sodium. J Pathol 209:376–383PubMedCrossRef

38.

Miehlke S, Heymer P, Bethke B, Bastlein E, Meier E, Bartram HP, Wilhelms G, Lehn N, Dorta G, DeLarive J, Tromm A, Bayerdörffer E, Stolte M (2002) Budesonide treatment for collagenous colitis: a randomized, double-blind, placebo-controlled, multicenter trial. Gastroenterol 123:978–984CrossRef

39.

Tromm A, Griga T, Mollmann HW, May B, Muller KM, Fisseler-Eckhoff A (1999) Budesonide for the treatment of collagenous colitis: first results of a pilot trial. Am J Gastroenterol 94:1871–1875PubMedCrossRef

Titel: The Behavior of Matrix Metalloproteinase-9 in Lymphocytic Colitis, Collagenous Colitis and Ulcerative Colitis
verfasst von: Gábor Lakatos
Ferenc Sipos
Pál Miheller
István Hritz
Mária Zsófia Varga
Márk Juhász
Béla Molnár
Zsolt Tulassay
László Herszényi
Publikationsdatum: 01.01.2012
Verlag: Springer Netherlands
Erschienen in: Pathology & Oncology Research / Ausgabe 1/2012
Print ISSN: 1219-4956
Elektronische ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-011-9420-9

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

The Behavior of Matrix Metalloproteinase-9 in Lymphocytic Colitis, Collagenous Colitis and Ulcerative Colitis

Abstract

Neu im Fachgebiet Onkologie

Darf man die Behandlung eines Neonazis ablehnen?

Erhöhte Mortalität bei postpartalem Brustkrebs

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

Update Onkologie

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2012

Hepatoid Adenocarcinoma of the Colon: What Should We Target?

Correlation Analysis of JAK-STAT Pathway Components on Prognosis of Patients with Prostate Cancer

Extraskeletal Osteosarcoma of Subcutaneous Soft Tissue with Lymph Node and Skin Metastasis: A Case Report with Fluorescence in Situ Hybridization Analysis

Renal Cell Carcinoma with t(X;17)(p11.2;q25) in a 5-year-old Taiwanese Boy. A Case Report and Review of the Literature

Occasional Staining for p63 in Malignant Vascular Tumors: A Potential Diagnostic Pitfall

Immunohistochemical Study of the Angiogenetic Network of VEGF, HIF1α, VEGFR-2 and Endothelial Nitric Oxide Synthase (eNOS) in Human Breast Cancer

Neu im Fachgebiet Onkologie

Darf man die Behandlung eines Neonazis ablehnen?

Erhöhte Mortalität bei postpartalem Brustkrebs

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

Update Onkologie